French pharmaceutical company Servier has entered into a definitive agreement to purchase Day One Biopharmaceuticals (DAWN) in an all-cash transaction valued at approximately $2.5 billion. Following the announcement on Friday, March 6, DAWN shares climbed roughly 66% in premarket activity.
https://x.com/FenwickWest/status/2029944210065969265?s=20
The transaction terms establish a purchase price of $21.50 for each outstanding share of Day One common stock. This valuation represents a 68% premium compared to Thursday’s closing price and an 86% premium relative to the 30-day volume-weighted average price.
Day One Biopharmaceuticals, Inc., DAWN
Notably, the acquisition agreement does not include a financing contingency, eliminating a typical hurdle that often complicates merger completions. The transaction is projected to finalize during Q2 2026, subject to U.S. antitrust approval and a majority of DAWN shareholders tendering their shares.
Day One’s board of directors conducted a comprehensive evaluation and unanimously determined to recommend the tender offer to shareholders. The agreement includes customary non-solicitation clauses and establishes a termination fee of $87.7 million payable under specific circumstances if the deal fails to close.
Market participants weren’t entirely caught off guard by the announcement. DAWN shares had experienced upward movement on Wednesday following media reports suggesting potential acquisition interest, with Jazz Pharmaceuticals (JAZZ) and Ipsen (IPSEY) previously mentioned as potential acquirers.
The centerpiece of this acquisition is tovorafenib, Day One’s primary drug candidate designed to treat low-grade glioma — a brain tumor type. The therapy holds significant promise in pediatric oncology, which represents Day One’s core development focus.
For Servier, this transaction bolsters its rare oncology portfolio. The French pharmaceutical organization, which generated €6.9 billion in revenue during fiscal year 2024/25, currently allocates nearly 20% of branded product revenue toward research and development initiatives. Incorporating Day One’s therapeutic assets aligns with Servier’s strategic objective to strengthen its position in precision cancer treatments.
The acquisition will proceed through an all-cash tender offer mechanism, followed by a backend merger once all conditions are satisfied. The absence of a financing requirement from Servier signals strong deal certainty.
The $87.7 million termination fee offers Day One some financial protection should the transaction fail to materialize under specified circumstances.
Before this acquisition announcement, the latest analyst price target for DAWN was set at $17.00 per share with a Buy recommendation — significantly below the agreed-upon $21.50 acquisition price.
Day One’s market capitalization before the deal announcement was roughly $1.35 billion. The $2.5 billion transaction value illustrates the substantial premium Servier is willing to pay for access to Day One’s drug pipeline.
Day One operates from its headquarters in Brisbane, California. Upon deal completion, Servier — an independent French pharmaceutical organization with commercial presence across more than 130 countries — will assume complete ownership of the company.
The post Day One Biopharmaceuticals (DAWN) Stock Soars 66% on Servier Buyout Agreement appeared first on Blockonomi.
